A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury
Phase 2
124
about 1.2 years
18–80
16 sites in AZ, CA, KS +9
What this study is about
This trial is testing a treatment called AZD4144 for people with sepsis who also have acute kidney injury. Participants will receive either AZD4144 or a placebo intravenously once daily for 436 days, along with safety monitoring and other assessments. The goal is to compare specific kidney function measurements between those receiving AZD4144 and those receiving the placebo.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AZD4144
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Area Under the Curve (AUC) of 24-hour Creatinine Clearance (CrCl).
Secondary: AUC mSOFA score, AUC: Plasma IL-18, AUC: Plasma IL-6, AUC: Serum Creatinine, AUC: Serum Cystatin C, AUC: Urine IL-18, AUC: Urine IL-6, AUC: mGFR
Renal, Infectious